Loading…

uniQure N.V.QURECompetitor analysis, valuation and peers

United States · USD·Health Care›Biotechnology

Develops AAV-based gene therapies for rare genetic diseases; co-developed Hemgenix, the first approved hemophilia B gene therapy.

Momentum laggard 13
Mkt cap
$1.42B
US dollars, full cap
Free float
93%
of shares outstanding
$/day
$44.9M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-95.1 pp
WACC 9.3%
Hurdle
n/a
no reverse DCF
Next earnings
103 days
1 Mar 2027
Close · USD$20.30
1D-2.3%
1W-17.4%
1M-10.6%
3M-58.5%
6M-17.5%
YTD-15.2%
1Y-33.1%
ATR %8.9%
Beta0.74
52w lowhigh60.8% off high

What uniQure does

Develops AAV-based gene therapies for rare genetic diseases; co-developed Hemgenix, the first approved hemophilia B gene therapy.

Hemgenix, the hemophilia B gene therapy, is sold by CSL Behring, so uniQure's own income from it comes as milestone and royalty payments rather than product sales. With nothing else on the market, it finances its main programme, a one-time gene therapy delivered into the brain for Huntington's disease, with those payments and share sales.

Products and services

  • AMT-130 (Huntington's disease)
  • Hemgenix royalty (hemophilia B, with CSL Behring)
  • CNS gene therapy pipeline

Customers

  • Neurologists/hematologists (post-approval)
  • CSL Behring (Hemgenix commercial partner)

Where it sits in the supply chain

  • Health Care
  • Biotechnology
  • AAV gene therapy

What could go right

  • Hemgenix royalty growth
  • AMT-130 regulatory path toward approval

What could go wrong

  • Gene therapy manufacturing and scale-up risk
  • Clinical trial failure risk

Moat: narrow (IP / patents, process know-how). Pioneer in AAV gene therapy manufacturing with an approved product and a royalty stream from CSL Behring.

Headquarters: Amsterdam, Netherlands · Founded: 1998 · Employees: 221

Named competitors

uniQure at a glance

Size uniQure (QURE) is a United States Health Care company (Biotechnology) with a market value of $1.42B, the 2001st largest of 3,085 United States companies the cockpit tracks. Shares closed at $20.30 on 18 Nov 2026.

Performance Over six months the shares fell 17.5%, against -20.3% for the median peer and -2.2% for the United States market (cap-weighted) — 10th highest of 20 in its peer set.

Growth Revenue grew 28.0% over the last twelve months (peer median +20.3%); the operating margin is -1,026.9% (peer median -61.2%).

Valuation It trades at 65.4× enterprise value to sales against a peer median of 17.2× (6th most expensive of 17).

Capital Return on invested capital runs 95.1 points below its cost of capital (9.3% WACC).

Short interest Short interest is 12.1% of the free float (30 Oct 2026).

Next results Next results expected around 1 Mar 2027 (exchange calendar; dates can move).

Relative performance

10015020021 May 202621 Aug 202618 Nov 2026QURE 82Peer median 79
Six months, rebased to 100: uniQure against the median of its 20 peers (local-currency closes).

uniQure financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$20.2M$16.1M$27.1M$15.8M$106M
Revenue growth—-41%+71%-85%—
Gross profit$2.64M-$347,000-$3.85M-$9.69M$94.6M
EBITDA-$191M-$171M-$172M-$259M-$134M
Net income-$233M-$199M-$240M-$308M-$127M
Free cash flow-$193M-$178M-$186M-$153M-$163M
Capital expenditure$735,373$439,000$11.7M$7.15M$17.7M
Total debt$564M$537M$501M$533M$143M

Quarterly statements and history in the cockpit →

uniQure competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+100%+200%-25%0%+25%+50%688105ABSIIMCRANAB688765URGNRAPP26376881854588MSB087010TYRAKRSAQURE6-month return →1-month return →
Up and to the right = strong over both horizons. uniQure is the large dot.

Fundamentals: revenue growth against valuation

0%+500%+1,000%+1,500%0×500×1,000×688105ABSIIMCR6887654588MSB087010NUVBKRSAQURERevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. uniQure is the large dot.

uniQure competitors and peer comparison

Head to head with its named competitors (QURE vs SRPT vs BMRN vs PTCT)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
uniQure QURE$1.42B-17%+28%-1,027%65.4×n/a
Sarepta Therapeutics SRPT$1.56B-15%-19%0%0.9×-6.8%
BioMarin Pharmaceutical BMRN$11.9B+22%+20%19%4.2×8.2%
PTC Therapeutics PTCT$5.03B-15%-35%22%3.1×6.6%

How uniQure compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

uniQure against its 20 peers (data as of 18 Nov 2026)
MeasureQUREPeer medianRank in peer set
1-month return-10.6%-12.3%11th highest of 21
6-month return-17.5%-20.3%10th highest of 20
Distance from 52-week high-60.8%-45.9%4th lowest of 21
Revenue growth (TTM)+28.0%+20.3%8th highest of 17
Operating margin-1,026.9%-61.2%3rd lowest of 18
EV / Sales65.4×17.2×6th most expensive of 17
ROIC minus cost of capital-95.1 pp-15.4 pp3rd lowest of 10

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
uniQure QUREUnited States$1.42B-17%+28%-1,027%65.4×n/an/a
Nanjing Vazyme Biotech 688105.SSChina$1.42B+25%+16%-5%4.9×39.4%-2.5%
Absci ABSIUnited States$1.41B+65%-47%-9,155%835.7×n/an/a
Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh IMCRUnited States$1.44B-7%+13%-7%2.3×n/an/a
AnaptysBio ANABUnited States$1.40B-22%+13%62%7.9×0.5%+25.6%
Wuhan Healthgen Biotechnology 688765.SSChina$1.46B-51%+90%-297%205.0×n/an/a
UroGen Pharma URGNUnited States$1.46B-1%+159%-12%6.3×n/an/a
Rapport Therapeutics RAPPUnited States$1.39B-34%n/a-838%50.1×n/an/a
Fujian Haixi Pharmaceuticals 2637.HKHong Kong$1.47B-32%+25%33%n/an/an/a
CanSino Biologics 688185.SSChina$1.38B0%+30%-4%6.6×n/an/a
Oncolys BioPharma 4588.TJapan$1.37B+181%+1,749%-295%408.9×n/an/a
Intellia Therapeutics NTLAUnited States$1.37B-20%-8%-821%21.3×n/an/a
Mesoblast MSB.AXAustralia$1.49B-17%+556%-43%12.8×n/an/a
Peptron 087010.KSSouth Korea$1.49B-68%-13%-488%359.6×n/an/a
Tyra Bioscience TYRAUnited States$1.35B-41%n/an/an/an/an/a
TLC BioSciences 7924.TWOTaiwan$1.50Bn/an/an/an/an/an/a
Chengdu Olymvax Biopharmaceuticals 688319.SSChina$1.51B-37%+12%8%13.1×n/an/a
Generate Biomedicines GENBUnited States$1.34B-20%+56%-737%31.7×n/an/a
Nuvation Bio NUVBUnited States$1.34B-16%+654%-61%5.7×n/an/a
Korsana Biosciences KRSAUnited States$1.52B+54%-64%-5,277%1,058.7×n/an/a
Kailera Therapeutics KLRAUnited States$1.53B-41%n/an/an/an/an/a

Questions

Who are uniQure's main competitors?
Named competitors: Sarepta Therapeutics (SRPT), BioMarin Pharmaceutical (BMRN), PTC Therapeutics (PTCT). The cockpit's measured peer set (industry) also includes Nanjing Vazyme Biotech (688105.SS), Absci (ABSI), Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh (IMCR), AnaptysBio (ANAB), Wuhan Healthgen Biotechnology (688765.SS), UroGen Pharma (URGN).
Is uniQure expensive compared with its peers?
On ev / sales it trades at 65.4× against a peer median of 17.2×, 6th most expensive of 17 in its peer set.
How has uniQure stock performed?
Over six months to 18 Nov 2026 the shares returned -17.5% against -20.3% for the median peer; over one year -33.1%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.